



GIG  
CYMRU  
NHS  
WALES

Pwyllgor Gwasanaethau Iechyd  
Arbenigol Cymru (PGIAC)  
Welsh Health Specialised  
Services Committee (WHSSC)

## **WELSH HEALTH SPECIALISED SERVICES COMMITTEE JOINT COMMITTEE MEETING – JULY 2018**

The Welsh Health Specialised Services Committee held its latest public meeting on 10 July 2018. This briefing sets out the key areas of discussion and aims to ensure everyone is kept up to date with what is happening in Welsh Health Specialised Services.

The papers for the meeting are available at:

<http://www.whssc.wales.nhs.uk/2018-19-whssc-joint-committee>

### **Action log & matters arising**

Members noted the action log.

### **Chair's report**

The Chair verbally reported that the Cabinet Secretary for Health and Social Services had completed her appraisal. She reported that major trauma and gender identity services were given as an area for particular focus in the forthcoming year.

The Joint Committee received a written report providing an update on Chair's action taken concerning the adult thoracic surgery review consultation. Members ratified the Chair's action.

### **Managing Director's report**

The Joint Committee noted the content of the Managing Director's report and in particular updates on:

- Neonatal Interim Work Stream. Members noted that Aneurin Bevan UHB, as the provider-lead for the work stream, would submit a report to WHSSC imminently and that Management Group would consider the report as one of the key risks identified within the ICP that is expected to emerge in year.
- Thrombectomy / Stroke Commissioning
- Home Parenteral Nutrition
- Proton Beam Therapy
- Inherited Bleeding Disorders
- Sickle Cell and Thalassaemia. Members noted that this service was not currently commissioned by WHSSC and that this was a scoping exercise through the collective commissioning framework.

- BAHA and Cochlear. Members noted a significant increase in demand in South Wales, as well as the identification of a significant number of patients with BAHA implants that were due to become obsolete in 2018 and 2019.
- Critical Care. Members noted an increase in demand for critical care within specialised services.
- WHSSC Corporate Values. Sian Lewis, Managing Director reported that she had launched the new WHSSC Corporate Values on 5 July 2018. The Joint Committee were provided with a small card showing the values.

### **Use of crizotinib in the treatment of ROS1-positive advanced non small-cell lung cancer**

The Joint Committee received the report. Members noted that NICE had issued a Final Appraisal Document (FAD) guidance on 31 May 2018 recommending the use of crizotinib, within the Cancer Drugs Fund, as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed access agreement were followed. The Joint Committee approved the funding request for 2018/19, 2019/20 and beyond.

### **2018-21 ICP Key Risks expected to emerge in year – Cystic Fibrosis**

The Joint Committee received the report that set out the investment requirements for the All Wales Adult Cystic Fibrosis Centre to address the immediate clinical risk and service sustainability.

The Joint Committee noted that that Management Group had considered the proposals at the June meeting and that the Management Group Members had recognised the fragility of the current service and the need to stabilise the infrastructure in order that the service was able to manage the existing patient cohort and the expected patient growth in 2018/19. The Joint Committee also noted that the Management Group had supported the proposal to invest in the MDT on a recurrent basis, and the part year effect of the Premixed IV Antibiotics Service, but had requested that further work be undertaken by the provider to clarify the model and full year costs of the Premixed IV Antibiotics Service.

The Joint Committee approved the investment in the MDT on a recurrent basis, and the part year effect of the Premixed IV Antibiotic Service for the remainder of 2018/19. The Joint Committee agreed that the provider would need to submit a further proposal for recurrent funding for the Premixed IV Antibiotic Service for consideration as part of the 2019-21 Integrated Commissioning Plan.

## **Delivery Plan for the Five year Specialised Neurosciences Strategy – south, mid and west Wales**

The Joint Committee received a report and a presentation. The Joint Committee approved the delivery plan for first two years of the Specialised Neurosciences Strategy in south, mid and west Wales and noted the work underway to develop a delivery plan for north Powys and north Wales.

It was agreed that a further paper around the Incentivisation element of the Neurosciences Strategy would be brought to a future meeting.

### **Other reports received**

The Joint Committee received the integrated performance report and financial performance report. The Joint Committee also noted the update reports from the following joint sub committees and advisory groups:

- Quality & Patient Safety Committee. The Joint Committee agreed to receive the revised terms of reference outside the meeting and provide comment to the Committee Secretariat. The Joint Committee agreed to approve the terms of reference subject to no major comment received. The Joint Committee also noted the quoracy issues due to the low number of Non-Executive Directors. Additional Members were being actively sought.
- All Wales Individual Patient Funding Request Panel
- Welsh Renal Clinical Network.